Compare InMode Ltd (INMD) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs uniQure N.V. Ordinary Shares — how do they compare? InMode Ltd trades at $14.29 (market cap $823.46M), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is the larger of the two by market cap, and InMode Ltd is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| INMD | QURE | |
|---|---|---|
Market Cap | $823.46M | $1.48B |
Volume | 427,627 | 2,488,780 |
Sector | Health | Health |
52-Week High | $16.62 | $70.59 |
52-Week Low | $12.76 | $9.03 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $326.79M | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.305, showing minimal daily movement with a 0.03% gain. The stock maintains a bullish technical signal despite mixed indicators, with RSI suggesting mild overbought conditions. Fundamentally, the company demonstrates strong profitability with 76.52% gross margins and 20.69% net income margins, though 2026 guidance shows potential margin compression. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
The investment outlook balances attractive valuation metrics (P/E of 11.83, EV/EBITDA of 4.68) against cyclical industry headwinds and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings, while technicals suggest near-term consolidation around current levels. Key risks include US platform sales decline and execution on international growth strategy.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
